^
    Back
    Association details:
    Biomarker:ANIB1 overexpression
    Cancer:Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    Medicine (Baltimore)
    Title:

    The role of amplified in breast cancer 1 in breast cancer: A meta-analysis

    Published date:
    11/13/2020
    Excerpt:
    Nine eligible studies, including 6774 patients, were finally assessed by the current clinical meta-analysis...This analysis demonstrated that AIB1 overexpression is related to aggressive phenotypes and unfavorable clinical outcomes in BC, and might involve in tamoxifen resistance. AIB1 may be a new prognostic biomarker and therapeutic target in BC.
    DOI:
    10.1097/MD.0000000000023248
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Oncol Pharm Pract
    Title:

    PAX2 promoter methylation and AIB1 overexpression promote tamoxifen resistance in breast carcinoma patients

    Published date:
    01/28/2021
    Excerpt:
    Aberrant promoter methylation of PAX2 and overexpression of AIB1 was observed in tamoxifen resistance patients compared to the sensitive ones….Our results revealed that the aberration in PAX2 promoter methylation and AIB1 overexpression are associated with the tamoxifen response in breast carcinoma patients.
    DOI:
    10.1177/1078155221989404